J&J’s ICOTYDE Approval Signals Shift in Psoriasis Treatment Paradigm
Event summary
- Johnson & Johnson’s ICOTYDE (icotrokinra), an oral IL-23R targeted peptide, received FDA approval on March 18, 2026.
- ICOTYDE is the first oral peptide approved for moderate-to-severe plaque psoriasis in adults and pediatric patients (12+ years, ≥40kg).
- Phase 3 trials demonstrated 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% achieved PASI 90 response at Week 16.
- The approval is supported by the ICONIC clinical development program, evaluating ICOTYDE across various patient populations and head-to-head comparisons.
The big picture
The approval of ICOTYDE represents a significant advancement in psoriasis treatment, moving towards more targeted and convenient therapies. The International Psoriasis Council’s guidance emphasizing earlier systemic intervention creates a favorable market environment for oral therapies like ICOTYDE. J&J’s strategic focus on innovative medicine underscores its commitment to addressing unmet needs in immunology, potentially reshaping the competitive landscape within the $20 billion psoriasis therapeutics market.
What we're watching
- Market Adoption
- The speed of physician and patient adoption of ICOTYDE will depend on its perceived advantages over existing systemic therapies, particularly regarding ease of administration and safety profile.
- Competitive Response
- Competitors like Eli Lilly (deucravacitinib) and AbbVie (ustekinumab) will likely accelerate development or marketing efforts to counter ICOTYDE’s entry into the market.
- Expansion Potential
- J&J’s success in expanding ICOTYDE’s indications to other disease areas (psoriatic arthritis, ulcerative colitis, Crohn’s disease) will be a key driver of long-term revenue growth.
Related topics